About Us
Company Profile Mission Leadership
Senior Management Board of Directors Scientific Advisory Boards
Milestones Sustainability
Innovation
Discovery Translational Research Process Development Clinical Development Manufacturing
Products
Pipeline Core products
Osemitamab(TST001) TST002 TST003
Scientific Publications
Partnering
Investors
News & Events
Press Release In The News Events
Careers
Life in Transcenta Job Opportunity

TST198

Claudin 18.2

Target:: Claudin 18.2

Indication:: G/ GEJC and other Solid Tumors

Project Status:: Preclinical

TST198 is a first-in-class Claudin18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors. RDC offers a potential differentiated approach to address payload resistance in patients pre-exposed to antibody drug conjugates.